Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/801"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label | |
| rdf:type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_type | |
| ?:Evidence_value |
"0.55"
|
| ?:content |
"Route of administration: oral/iv
polymorphic enzyme: NO
study duration: 7 days simvastatin only, 8 days simva and clarithromycin
dose: single dose of .250g clarithromycin oral vs .250g i.v. infusion at three seperate times 1 week apart
population: 20 men
ages:18-40
description:
The absolute bioavailability of clarithromycin, a new macrolide antimicrobial agent, was assessed in a three-way, randomized, single-dose, crossover study conducted with 22 healthy volunteers, 19 of whom provided analyzable study data. The bioavailability parameters of two 250-mg oral tablet formulations were calculated with reference to an identical dose administered by intravenous infusion of the lactobionate salt. After adjustment for formulation potency, the mean absolute bioavailabilities of the two oral formulations were 52 and 55%, on the basis of the appearance of parent compound in the systemic circulation."
|
| dc:creator | |
| dc:date |
"06/05/2007 11:46:56"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ clarithromycin_bioavailability_continuous_value, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1944 }